Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ATOS NYSE:MBX NASDAQ:PRTC NASDAQ:RZLT On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.84+2.0%$0.82$0.55▼$1.66$106.33M1.1458,809 shs493,903 shsMBXMBX Biosciences$10.83+9.1%$13.09$4.81▼$27.50$333.59MN/A329,784 shs684,563 shsPRTCPureTech Health$15.80-3.1%$17.97$13.30▼$24.99$393.59M1.115,010 shs1,787 shsRZLTRezolute$7.69-3.5%$6.36$2.21▼$8.34$693.36M0.03820,391 shs612,286 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+2.02%+6.57%+6.86%+1.12%-44.75%MBXMBX Biosciences+9.06%-6.23%-16.37%+4.44%+1,082,999,900.00%PRTCPureTech Health-3.13%-3.28%-10.96%-19.43%-20.56%RZLTRezolute-3.51%-3.88%+18.86%+83.10%+49.61%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeATOSAtossa Genetics$0.84+2.0%$0.82$0.55▼$1.66$106.33M1.1458,809 shs493,903 shsMBXMBX Biosciences$10.83+9.1%$13.09$4.81▼$27.50$333.59MN/A329,784 shs684,563 shsPRTCPureTech Health$15.80-3.1%$17.97$13.30▼$24.99$393.59M1.115,010 shs1,787 shsRZLTRezolute$7.69-3.5%$6.36$2.21▼$8.34$693.36M0.03820,391 shs612,286 shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceATOSAtossa Genetics+2.02%+6.57%+6.86%+1.12%-44.75%MBXMBX Biosciences+9.06%-6.23%-16.37%+4.44%+1,082,999,900.00%PRTCPureTech Health-3.13%-3.28%-10.96%-19.43%-20.56%RZLTRezolute-3.51%-3.88%+18.86%+83.10%+49.61%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceATOSAtossa Genetics 3.33Buy$6.17634.30% UpsideMBXMBX Biosciences 3.00Buy$37.63247.41% UpsidePRTCPureTech Health 0.00N/AN/AN/ARZLTRezolute 3.20Buy$11.6751.71% UpsideCurrent Analyst Ratings BreakdownLatest ATOS, PRTC, MBX, and RZLT Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/3/2025RZLTRezoluteHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$14.008/5/2025MBXMBX BiosciencesMizuhoSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.007/16/2025MBXMBX BiosciencesOppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$38.00(Data available from 9/13/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookATOSAtossa GeneticsN/AN/AN/AN/A$0.57 per shareN/AMBXMBX BiosciencesN/AN/AN/AN/AN/AN/APRTCPureTech Health$4.83M78.93$2.31 per share6.84$17.04 per share0.93RZLTRezoluteN/AN/AN/AN/A$2.19 per shareN/ACompare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateATOSAtossa Genetics-$25.50M-$0.23N/AN/AN/AN/A-40.28%-37.10%11/11/2025 (Estimated)MBXMBX BiosciencesN/A-$4.54N/AN/AN/AN/AN/AN/AN/APRTCPureTech Health$27.78MN/A0.00N/AN/AN/AN/AN/AN/ARZLTRezolute-$68.46M-$1.15N/AN/AN/AN/A-70.09%-63.08%9/18/2025 (Estimated)Latest ATOS, PRTC, MBX, and RZLT EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/18/2025Q4 2025RZLTRezolute-$0.22N/AN/AN/AN/AN/A8/12/2025Q2 2025ATOSAtossa Genetics-$0.06-$0.07-$0.01-$0.07N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthATOSAtossa GeneticsN/AN/AN/AN/AN/AMBXMBX BiosciencesN/AN/AN/AN/AN/APRTCPureTech HealthN/AN/AN/AN/AN/ARZLTRezoluteN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioATOSAtossa GeneticsN/A9.179.17MBXMBX BiosciencesN/AN/AN/APRTCPureTech HealthN/A8.499.33RZLTRezoluteN/A8.438.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipATOSAtossa Genetics12.74%MBXMBX BiosciencesN/APRTCPureTech Health0.04%RZLTRezolute82.97%Insider OwnershipCompanyInsider OwnershipATOSAtossa Genetics7.60%MBXMBX Biosciences52.19%PRTCPureTech Health5.30%RZLTRezolute18.39%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableATOSAtossa Genetics8129.17 million119.35 millionOptionableMBXMBX Biosciences3633.59 millionN/AN/APRTCPureTech Health10024.13 million22.85 millionNot OptionableRZLTRezolute4087.00 million71.00 millionOptionableATOS, PRTC, MBX, and RZLT HeadlinesRecent News About These CompaniesRezolute (NASDAQ:RZLT) Reaches New 52-Week High - Here's Why2 hours ago | marketbeat.comCubist Systematic Strategies LLC Grows Stock Holdings in Rezolute, Inc. $RZLT4 hours ago | marketbeat.comRezolute, Inc. (RZLT) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference TranscriptSeptember 12 at 10:03 AM | seekingalpha.comRezolute (RZLT) Expected to Announce Quarterly Earnings on ThursdaySeptember 12 at 2:08 AM | marketbeat.comWalleye Capital LLC Decreases Stock Position in Rezolute, Inc. $RZLTSeptember 8, 2025 | marketbeat.comRezolute, Inc. $RZLT Shares Bought by OMERS ADMINISTRATION CorpSeptember 6, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Earns "Buy" Rating from HC WainwrightSeptember 6, 2025 | americanbankingnews.comRezolute, Inc. (NASDAQ:RZLT) Given Consensus Recommendation of "Buy" by AnalystsSeptember 5, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Receives "Buy" Rating from HC WainwrightSeptember 5, 2025 | marketbeat.comADAR1 Capital Management LLC Cuts Stock Position in Rezolute, Inc. $RZLTSeptember 4, 2025 | marketbeat.comNantahala Capital Management LLC Sells 1,566,587 Shares of Rezolute, Inc. $RZLTSeptember 3, 2025 | marketbeat.comRezolute Announces Alignment with FDA on Streamlined Design for Ongoing Phase 3 Trial of Ersodetug in Tumor HyperinsulinismSeptember 2, 2025 | globenewswire.comRezolute Aligns with FDA on Phase 3 Trial DesignSeptember 2, 2025 | tipranks.comVelan Capital Investment Management LP Reduces Stock Holdings in Rezolute, Inc. $RZLTAugust 31, 2025 | marketbeat.comAffinity Asset Advisors LLC Buys 125,000 Shares of Rezolute, Inc. $RZLTAugust 28, 2025 | marketbeat.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - Still a Buy?August 27, 2025 | marketbeat.comRezolute, Inc. to Present at Upcoming Investor Conferences in September 2025August 27, 2025 | quiverquant.comQRezolute to Participate in Upcoming Investor ConferencesAugust 27, 2025 | globenewswire.comRezolute appoints Karnawat as Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute Appoints New Chief Commercial OfficerAugust 20, 2025 | msn.comRezolute (NASDAQ:RZLT) Hits New 52-Week High - What's Next?August 20, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesBuffett Makes Big Moves Outside of UNH: A Buy and Sell BreakdownBy Leo Miller | August 18, 20253 Companies That Will Profit From Trump's Semiconductor TariffsBy Jordan Chussler | August 14, 20253 Robotics Stocks at the Heart of the Robotics RevolutionBy Chris Markoch | August 21, 2025Next-Gen Defense: 3 Stocks Riding the New Global Arms RaceBy Nathan Reiff | August 18, 2025Kratos Keeps Climbing After Q2, But Valuation Risk LoomsBy Leo Miller | August 18, 2025ATOS, PRTC, MBX, and RZLT Company DescriptionsAtossa Genetics NASDAQ:ATOS$0.84 +0.02 (+2.02%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$0.84 0.00 (-0.33%) As of 09/12/2025 07:32 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Atossa Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops medicines in the areas of unmet medical need in oncology for women breast cancer and other conditions in the United States. The company's lead drug candidate is oral (Z)-endoxifen, an active metabolite of tamoxifen, which is in Phase II clinical trials to treat and prevent breast cancer. It also develops immunotherapy/chimeric antigen receptor therapy programs. The company was formerly known as Atossa Genetics Inc. and changed its name to Atossa Therapeutics, Inc. in January 2020. Atossa Therapeutics, Inc. was founded in 2008 and is headquartered in Seattle, Washington.MBX Biosciences NYSE:MBX$10.83 +0.90 (+9.06%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$11.06 +0.23 (+2.12%) As of 09/12/2025 04:57 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MBX Biosciences, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision peptide therapies for the treatment of endocrine and metabolic disorders. Its lead product candidate is MBX 2109, a parathyroid hormone peptide prodrug, which is in Phase 2 clinical trial designed as a potential long-acting hormone replacement therapy for the treatment of chronic hypoparathyroidism. The company is also developing MBX 1416, a long-acting glucagon-like peptide-1 (GLP-1) receptor antagonist that is in Phase 1 clinical trial designed as a potential therapy for post-bariatric hypoglycemia, a chronic complication of bariatric surgery. In addition, it is developing MBX 4291, a lead obesity product candidate, which is in investigational new drug-enabling studies designed as a long-acting and highly potent GLP-1 and glucose-dependent insulinotropic polypeptide receptor co-agonist prodrug for treating obesity and co-morbidities. The company was founded in 2018 and is based in Carmel, Indiana.PureTech Health NASDAQ:PRTC$15.60 -0.71 (-4.35%) As of 09/12/2025 04:00 PM Eastern This is a fair market value price provided by Polygon.io. Learn more.PureTech Health plc, engages in the development and commercialization of biotechnology and pharmaceutical solutions in the United States. The company is developing LYT-100, which is under Phase 2 stage, to treat idiopathic pulmonary fibrosis (IPF); and LYT-200, a IgG4 monoclonal antibody, currently under Phase 1/2 stage, targeting galectin-9 for treating solid tumors and hematological malignancies. It also develops SPT-300, an oral drug of allopregnanolone for the treatment of anxious depression; SPT-320, a novel prodrug of agomelatine for the treatment of generalized anxiety disorder; and SPT-348, a prodrug of a non-hallucinogenic neuroplastogen for the treatment of mood and other neuropsychiatric disorders. In addition, the company is developing hydrogels to enable the oral administration of peptide therapeutics in preclinical development. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.Rezolute NASDAQ:RZLT$7.69 -0.28 (-3.51%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$7.74 +0.05 (+0.65%) As of 09/12/2025 07:33 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Rezolute, Inc., a clinical stage biopharmaceutical company, develops therapies for metabolic diseases associated with chronic glucose imbalance in the United States. The company's lead product candidate is RZ358, a human monoclonal antibody that is in Phase 2b clinical trial for the treatment of congenital hyperinsulinism, an ultra-rare pediatric genetic disorder. It is also developing RZ402, an oral plasma kallikrein inhibitor, which is in clinical trial for the chronic treatment of diabetic macular edema. The company was formerly known as AntriaBio, Inc. and changed its name to Rezolute, Inc. in December 2017. Rezolute, Inc. was incorporated in 2010 and is headquartered in Redwood City, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Vanguard’s VUG ETF: The Ultimate Growth ETF for Your Portfolio Tesla's U.S. Market Is At An 8-Year Low... How Bad Could It Get? Not Just NVDA: 3 Semiconductor Stocks Struggling This Quarter Broadcom Gets Big Upgrades: How High Analysts See Shares Going Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
